Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $651.3 million.

  • Phathom Pharmaceuticals' Total Non-Current Liabilities rose 15.60% to $651.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $651.3 million, marking a year-over-year increase of 15.60%. This contributed to the annual value of $620.4 million for FY2024, which is 30.09% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Total Non-Current Liabilities stood at $651.3 million, which was up 1.05% from $644.6 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $651.3 million in Q3 2025 and a low of $103.5 million during Q1 2022.
  • For the 3-year period, Phathom Pharmaceuticals' Total Non-Current Liabilities averaged around $484.5 million, with its median value being $542.8 million (2024).
  • Data for Phathom Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY spiked of 127.86% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $232.1 million in 2022, then spiked by 105.45% to $476.9 million in 2023, then soared by 30.09% to $620.4 million in 2024, then rose by 15.60% to $651.3 million in 2025.
  • Its last three reported values are $651.3 million in Q3 2025, $644.6 million for Q2 2025, and $621.1 million during Q1 2025.